AbbVie (ABBV) vs AstraZeneca (AZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AbbVie (ABBV) has outperformed AstraZeneca (AZN) over the past year, gaining 16.5% versus a loss of 6.8%. Over five years, ABBV leads with a +148.2% price change compared with +32.9% for AZN. AbbVie is the larger company by market cap ($479.52 billion vs $248.33 billion), about 1.9 times the size, while AstraZeneca is growing revenue faster (+8.6% vs +8.6%).
On valuation, AstraZeneca trades at a lower forward P/E (13.8x vs 16.7x for AbbVie). AbbVie offers the higher dividend yield (2.52% vs 2.02%). AstraZeneca converts more of its revenue into profit, with a net margin of 17.4% versus 6.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABBV | AZN |
|---|---|---|
| Share price | $271.36 | $160.12 |
| Market cap | $479.52B | $248.33B |
| 1-day change | +1.75% | +0.95% |
| YTD return | +18.76% | -12.91% |
| 1-year return | +16.55% | -6.77% |
| 5-year return | +148.20% | +32.95% |
| P/E ratio (TTM) | 76.66 | 23.93 |
| Forward P/E | 16.69 | 13.85 |
| EPS (TTM) | $3.54 | $6.69 |
| Dividend yield | 2.52% | 2.02% |
| Annual dividend | $6.83 | $3.23 |
| Revenue (latest FY) | $61.16B | $58.74B |
| Revenue growth (YoY) | +8.57% | +8.63% |
| Net income (latest FY) | $4.23B | $10.22B |
| Gross margin | 70.24% | 81.90% |
| Operating margin | 24.65% | 23.40% |
| Net margin | 6.91% | 17.41% |
| 52-week high | $274.94 | $212.71 |
| 52-week low | $190.75 | $153.41 |
| Distance from 52-week high | -1.30% | -24.72% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +3.48% | +31.99% |
| Average volume | 4.86M | 3.41M |
| Shares outstanding | 1.77B | 1.55B |
| Employees | 57,000 | 96,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABBV has outperformed AZN by 23.3 percentage points over the past year.
- AbbVie trades at a higher earnings multiple (76.7x vs 23.9x trailing P/E).
- AstraZeneca is more profitable, keeping 17.4 cents of every revenue dollar as net income versus 6.9 cents for AbbVie.
About AbbVie
ABBV stock →AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees
About AstraZeneca
AZN stock →AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
Health Care · Biotechnology: Pharmaceutical Preparations · 96,100 employees
ABBV vs AZN FAQ
Which is bigger, AbbVie or AstraZeneca?
AbbVie (ABBV) is larger, with a market capitalization of $479.52B compared with $248.33B for AstraZeneca (AZN).
Which stock has performed better over the past year, ABBV or AZN?
ABBV returned +16.55% over the past 12 months, compared with -6.77% for AZN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABBV or AZN?
AZN has the lower trailing P/E at 23.9, versus 76.7 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AbbVie or AstraZeneca?
AbbVie has the higher yield at 2.52%, compared with 2.02% for AstraZeneca.
Are AbbVie and AstraZeneca in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.